Novan, Inc. announced Michelle Patterson as its new vice president of project management in a press release Tuesday.

Patterson will manage product portfolio milestones across the company including regulatory, clinical and manufacturing units.

Patterson will also lead coordination of Novan’s application for SB206, a gel the company is testing for the treatment of viral skin infections. The company plans to submit a NDA for the gel if test results, expected in the first quarter of 2020, are positive.

Patterson most recently served as senior director of program management with Urovant Sciences.

“With Phase 3 molluscum pivotal trials well underway and results expected no later than early in the first quarter of 2020, Michelle will add tremendous value to our process, approach and project management mindset in order to be prepared for a potential NDA submission,” said Paula Brown Stafford, president and chief operating officer of Novan.

Novan is a clinical development-stage biotechnology company focused on utilizing nitric oxide to treat a range of diseases.

Shares of Novan were trading at $2.12 per share Wednesday afternoon, up 7 cents.